All data are based on the daily closing price as of October 8, 2025
h
Hugel
145020.KQ
203.75 USD
-8.36
-3.94%
Overview
Last close
203.75 usd
Market cap
2.20B usd
52 week high
286.69 usd
52 week low
138.09 usd
Target price
320.77 usd
Valuation
P/E
N/A
Forward P/E
18.622
Price/Sales
7.6415
Price/Book Value
3.5874
Enterprise Value
1.85B usd
EV/Revenue
6.5269
EV/EBITDA
13.2135
Key financials
Revenue TTM
282.96M usd
Gross Profit TTM
220.41M usd
EBITDA TTM
148.29M usd
Earnings per Share
N/A usd
Dividend
N/A usd
Total assets
743.98M usd
Net debt
N/A usd
About
Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. It also provides hyaluronic acid filler under the Dermalax, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices under BlueRose brand name. Hugel, Inc. was founded in 2001 and is headquartered in Chuncheon-si, South Korea.